期刊
ONCOIMMUNOLOGY
卷 1, 期 1, 页码 48-55出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.1.1.18344
关键词
hepatocellular carcinoma; hepatitis; cirrhosis; alpha-fetoprotein; cancer vaccine; combination therapies
资金
- University of Pittsburgh Cancer Institute
- NCI [RO1 CA 138635]
- UPCI CCSG award [P30CA047904]
Current therapies for advanced hepatocellular carcinoma (HCC) are marginally effective and exacerbate underlying liver disease. The ability of immunotherapy to elicit nontoxic, systemic, long-lived anti-tumor activity makes it particularly well-suited for use in the setting of HCC. While therapeutic benefit has been achieved in early clinical trials, the efficacy of immune-based therapies is limited by several unique properties of HCC, most notably the inherently tolerogenic character of the liver in both healthy and diseased (chronically-infected or tumor-bearing) states. Therapeutic regimens that both counteract these immunosuppressive mechanisms and amplify tumor-specific immunity are expected to profoundly improve clinical outcomes for HCC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据